330 related articles for article (PubMed ID: 19825371)
1. Ribonucleases as potential modalities in anticancer therapy.
Ardelt W; Ardelt B; Darzynkiewicz Z
Eur J Pharmacol; 2009 Dec; 625(1-3):181-9. PubMed ID: 19825371
[TBL] [Abstract][Full Text] [Related]
2. Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.
Ardelt W; Shogen K; Darzynkiewicz Z
Curr Pharm Biotechnol; 2008 Jun; 9(3):215-25. PubMed ID: 18673287
[TBL] [Abstract][Full Text] [Related]
3. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.
Boix E; Wu Y; Vasandani VM; Saxena SK; Ardelt W; Ladner J; Youle RJ
J Mol Biol; 1996 Apr; 257(5):992-1007. PubMed ID: 8632481
[TBL] [Abstract][Full Text] [Related]
4. Cytostatic and cytotoxic properties of Amphinase: a novel cytotoxic ribonuclease from Rana pipiens oocytes.
Ardelt B; Ardelt W; Pozarowski P; Kunicki J; Shogen K; Darzynkiewicz Z
Cell Cycle; 2007 Dec; 6(24):3097-102. PubMed ID: 18073526
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.
Rybak SM; Pearson JW; Fogler WE; Volker K; Spence SE; Newton DL; Mikulski SM; Ardelt W; Riggs CW; Kung HF; Longo DL
J Natl Cancer Inst; 1996 Jun; 88(11):747-53. PubMed ID: 8637029
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (Ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-kappaB.
Tsai SY; Ardelt B; Hsieh TC; Darzynkiewicz Z; Shogen K; Wu JM
Int J Oncol; 2004 Dec; 25(6):1745-52. PubMed ID: 15547713
[TBL] [Abstract][Full Text] [Related]
7. [Onconase: a ribonuclease with antitumor activity].
Zwolińska M; Smolewski P
Postepy Hig Med Dosw (Online); 2010 Feb; 64():58-66. PubMed ID: 20173221
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis.
Iordanov MS; Ryabinina OP; Wong J; Dinh TH; Newton DL; Rybak SM; Magun BE
Cancer Res; 2000 Apr; 60(7):1983-94. PubMed ID: 10766189
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of activation-induced apoptosis of lymphocytes by the cytotoxic ribonuclease onconase (Ranpirnase).
Halicka DH; Pozarowski P; Ita M; Ardelt WJ; Mikulski SM; Shogen K; Darzynkiewicz Z
Int J Oncol; 2002 Dec; 21(6):1245-50. PubMed ID: 12429974
[TBL] [Abstract][Full Text] [Related]
10. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity.
Wu Y; Mikulski SM; Ardelt W; Rybak SM; Youle RJ
J Biol Chem; 1993 May; 268(14):10686-93. PubMed ID: 8486718
[TBL] [Abstract][Full Text] [Related]
11. On the track of antitumour ribonucleases.
Benito A; Ribó M; Vilanova M
Mol Biosyst; 2005 Oct; 1(4):294-302. PubMed ID: 16880994
[TBL] [Abstract][Full Text] [Related]
12. A human ribonuclease induces apoptosis associated with p21WAF1/CIP1 induction and JNK inactivation.
Castro J; Ribó M; Navarro S; Nogués MV; Vilanova M; Benito A
BMC Cancer; 2011 Jan; 11():9. PubMed ID: 21223552
[TBL] [Abstract][Full Text] [Related]
13. Single amino acid substitutions at the N-terminus of a recombinant cytotoxic ribonuclease markedly influence biochemical and biological properties.
Newton DL; Boque L; Wlodawer A; Huang CY; Rybak SM
Biochemistry; 1998 Apr; 37(15):5173-83. PubMed ID: 9548748
[TBL] [Abstract][Full Text] [Related]
14. Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy.
Lee I
Expert Opin Biol Ther; 2008 Jun; 8(6):813-27. PubMed ID: 18476793
[TBL] [Abstract][Full Text] [Related]
15. Interferon enhances the activity of the anticancer ribonuclease, onconase.
Vasandani VM; Castelli JC; Hott JS; Saxena S; Mikulski SM; Youle RJ
J Interferon Cytokine Res; 1999 May; 19(5):447-54. PubMed ID: 10386856
[TBL] [Abstract][Full Text] [Related]
16. Biological Activities of Secretory RNases: Focus on Their Oligomerization to Design Antitumor Drugs.
Gotte G; Menegazzi M
Front Immunol; 2019; 10():2626. PubMed ID: 31849926
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic activity of the amphibian ribonucleases onconase and r-amphinase on tumor cells from B cell lymphoproliferative disorders.
Smolewski P; Witkowska M; Zwolinska M; Cebula-Obrzut B; Majchrzak A; Jeske A; Darzynkiewicz Z; Ardelt W; Ardelt B; Robak T
Int J Oncol; 2014 Jul; 45(1):419-25. PubMed ID: 24789756
[TBL] [Abstract][Full Text] [Related]
18. Antibody-onconase conjugates: cytotoxicity and intracellular routing.
Rybak SM
Curr Pharm Biotechnol; 2008 Jun; 9(3):226-30. PubMed ID: 18673288
[TBL] [Abstract][Full Text] [Related]
19. Arginine residues are more effective than lysine residues in eliciting the cellular uptake of onconase.
Sundlass NK; Raines RT
Biochemistry; 2011 Nov; 50(47):10293-9. PubMed ID: 21980976
[TBL] [Abstract][Full Text] [Related]
20. Activating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of Onconase.
Vert A; Castro J; Ribó M; Benito A; Vilanova M
Oncotarget; 2017 Feb; 8(7):11692-11707. PubMed ID: 28035074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
